KYNTRA BIO, INC. Total Assets

• KYNTRA BIO, INC. showed a decrease of -44.3% in Total Assets from 2024 to 2025.
• This data is from KYNTRA BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: $435.54 million | Q2 2015: $541.40 million | Q3 2015: $499.25 million | Q1 2016: $442.54 million | Q2 2016: $499.13 million | Q3 2016: $486.21 million | Q1 2017: $441.76 million | Q2 2017: $542.64 million | Q3 2017: $894.89 million | Q1 2018: $867.61 million | Q2 2018: $869.92 million | Q3 2018: $855.64 million | Q1 2019: $812.40 million | Q2 2019: $915.07 million | Q3 2019: $893.96 million | Q1 2020: $824.38 million | Q2 2020: $807.68 million | Q3 2020: $812.02 million | Q1 2021: $787.30 million | Q2 2021: $808.62 million | Q3 2021: $850.51 million | Q1 2022: $745.93 million | Q2 2022: $686.79 million | Q3 2022: $608.84 million | Q1 2023: $538.54 million | Q2 2023: $515.13 million | Q3 2023: $460.43 million | Q1 2024: $365.87 million | Q2 2024: $293.20 million | Q3 2024: $264.42 million | Q1 2025: $165.21 million | Q2 2025: $178.06 million | Q3 2025: $137.01 million.
• Over the full 12 years of available data (2014 to 2025), KYNTRA BIO, INC.'s Total Assets has declined by 75.3%.
• Historical annual values: Fiscal year 2025: $119.59 million | Fiscal year 2024: $214.53 million | Fiscal year 2023: $423.53 million | Fiscal year 2022: $610.09 million | Fiscal year 2021: $773.82 million | Fiscal year 2020: $826.84 million | Fiscal year 2019: $857.40 million | Fiscal year 2018: $880.60 million | Fiscal year 2017: $898.65 million | Fiscal year 2016: $469.55 million | Fiscal year 2015: $470.57 million | Fiscal year 2014: $483.53 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026